Related Experiment Videos
Left ventricular hypertrophy: impact of calcium channel blocker therapy
1Clinical Hypertension Laboratory, Ochsner Clinic, New Orleans, Louisiana 70121.
Insights
Concentric left ventricular hypertrophy (LVH) increases cardiovascular risk. Certain antihypertensive drugs effectively reduce LVH and ventricular ectopy, unlike diuretics.
Area of Science:
- Cardiology
- Hypertension Research
- Pharmacology
Background:
- Concentric left ventricular hypertrophy (LVH) is a common cardiac response to sustained arterial hypertension.
- LVH significantly elevates the risk of sudden death, myocardial infarction, and other cardiovascular morbidities.
- Sequelae of LVH include ventricular ectopy, impaired contractility, ischemia, and reduced ventricular filling.
Purpose of the Study:
- To evaluate the impact of antihypertensive therapies on left ventricular hypertrophy (LVH) and associated cardiac sequelae.
- To determine if antihypertensive agents can prevent or reduce target organ damage beyond blood pressure reduction.
- To compare the efficacy of different antihypertensive drug classes in managing LVH and ventricular ectopy.
Main Methods:
- Analysis of data from the Framingham cohort to assess cardiovascular risk in patients with LVH.
- Review of studies investigating the effects of various antihypertensive agents (calcium channel blockers, ACE inhibitors, antiadrenergic drugs, beta blockers, diuretics) on LVH.
- Assessment of ventricular ectopy and left ventricular filling in response to different antihypertensive treatments.
Main Results:
- Calcium channel blockers, ACE inhibitors, and antiadrenergic drugs have demonstrated efficacy in reducing LVH and improving left ventricular filling.
- Calcium channel blockers were shown to diminish ventricular ectopy concurrently with LVH reduction.
- Diuretic therapy, while lowering blood pressure, did not significantly reduce LVH or suppress ventricular ectopy.
Conclusions:
- Antihypertensive therapy offers benefits beyond blood pressure control, including regression of left ventricular hypertrophy.
- Specific agents like calcium channel blockers show promise in mitigating LVH-related complications such as ventricular ectopy.
- Further research is needed to confirm whether these cardiac benefits translate into improved cardiovascular morbidity and mortality in patients with LVH.
Abstract:
Left ventricular hypertrophy (LVH) of the concentric type is the classic cardiac adaptation to sustained arterial hypertension. Data from the Framingham cohort have shown that patients with LVH have a severalfold higher risk of sudden death, acute myocardial infarction, and other cardiovascular morbidity than those with normal hearts. Common sequelae of LVH are ventricular ectopy, impaired ventricular contractility, myocardial ischemia, and decreased left ventricular filling. The benefits of antihypertensive therapy should not be limited to lowering arterial pressure, but should extend to preventing or reducing target organ damage. A variety of antihypertensive agents, such as calcium channel blockers, angiotensin-converting enzyme inhibitors, antiadrenergic drugs, and, to a lesser extent, beta blockers, have been shown to reduce LVH and to improve left ventricular filling. We have shown that calcium channel blockers diminish ventricular ectopy in parallel with the reduction of LVH, whereas antihypertensive therapy with diuretics neither reduced LVH nor suppressed ventricular ectopy, although it lowered arterial pressure to a similar extent. Whether or not these cardiac changes with antihypertensive therapies will improve cardiovascular morbidity and mortality in patients with LVH remains to be documented.